EUVIMEDEUVIMED entdecken
Open Access

A Skin Testing Strategy for Non–IgE-Mediated Reactions Associated With Vancomycin

Siyan Lyu, Eric T Oliver, Melanie C Dispenza, Kristin L Chichester, Jennifer Hoffman, Donald W MacGlashan, N Franklin Adkinson, Elizabeth J Phillips, Santiago Alvarez-Arango

The Journal of Allergy and Clinical Immunology: In Practice · 2024-11 · 12 (11) · 3025-3033.e6

DOI: 10.1016/j.jaip.2024.07.028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2024-11. Verfasst von Siyan Lyu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Johns Hopkins University, Baltimore, Md. Hauptthemen laut MEDLINE: Vancomycin, Drug Hypersensitivity. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NHGRI NIH HHS, NIAMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Vancomycin infusion reaction (VIR), reportedly mediated through Mas-Related G Protein-Coupled Receptor-X2, is the primary vancomycin-induced immediate drug reaction. Clinically, distinguishing the underlying drug-induced immediate drug reaction mechanisms is crucial for future treatment strategies, including drug restriction, re-administration, and pretreatment considerations. However, the lack of validated diagnostic tests makes this challenging, often leading to unnecessary drug restriction. OBJECTIVE: To determine whether intradermal tests (IDTs) and, separately, the basophil activation test (BAT) differentiate VIR from vancomycin-tolerant subjects. METHODS: This was a cross-sectional study of vancomycin-exposed adults with and without a history of VIR. Data on demographics, allergy-related comorbidities, history of vancomycin exposures, and VIR characteristics were collected. IDT with vancomycin was performed. IDT dose-response EC50, IDT-related local symptoms, and BAT results were compared between groups. RESULTS: A total of 11 VIR and 10 vancomycin-tolerant subjects were enrolled. The most reported VIR symptoms were pruritus (82%), flushing (82%), hives (46%), angioedema (27%), and dyspnea (19%). The IDT dose-response mean EC50 was 328 μg/mL (95% CI, 296-367) in the VIR versus 1166 μg/mL (95% CI, 1029-1379) in the tolerant group (P < .0001). All VIR subjects reported IDT-related local pruritus compared with 60% of tolerant subjects (P = .0185). The %CD63+ basophils were consistently less than 2%, without significant differences between groups (P < .54). CONCLUSIONS: Variations in skin test methodologies could help identify other immediate drug reaction mechanisms beyond IgE. This skin test protocol holds the potential for identifying VIR, particularly in cases where patients have received multiple drugs while BAT is insufficient. Future studies will validate and delineate its predictive value, assessing the risk of VIR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VancomycinDrug HypersensitivityHumansFemaleMaleMiddle AgedCross-Sectional StudiesAdultAnti-Bacterial AgentsAgedSkin TestsReceptors, G-Protein-CoupledBasophil Degranulation TestBasophilsImmunoglobulin ENerve Tissue ProteinsReceptors, Neuropeptide

Stichwörter der Autor:innen

Basophil activation testDose-response curveDrug allergyImmediate drug reactionMRGPRX2MRGPRX2 ligandsNon-IgE-mediated immediate drug reactionSkin testVancomycin infusion reaction

Substanzen

VancomycinAnti-Bacterial AgentsMRGPRX2 protein, humanReceptors, G-Protein-CoupledImmunoglobulin ENerve Tissue ProteinsReceptors, Neuropeptide

Autor:innen und Institutionen

  • Johns Hopkins University, Baltimore, Md.
  • Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Md.
  • Division of Clinical Pharmacology, Departments of Medicine and Pharmacology and Molecular Science, Johns Hopkins School of Medicine, Baltimore, Md.
  • Center for Drug Safety and Immunology, Departments of Medicine, Dermatology, Pharmacology, Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tenn.
  • Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Md; Division of Clinical Pharmacology, Departments of Medicine and Pharmacology and Molecular Science, Jo…

Förderung

  • NIAID NIH HHS
  • NHGRI NIH HHS
  • NIAMS NIH HHS
  • NCATS NIH HHS
  • American Academy of Allergy Asthma and Immunology
  • NCATS

Zitieren

APA

Lyu, S., Oliver, E. T., Dispenza, M. C., Chichester, K. L., Hoffman, J., MacGlashan, D. W., Adkinson, N. F., Phillips, E. J., & Alvarez-Arango, S. (2024). A Skin Testing Strategy for Non–IgE-Mediated Reactions Associated With Vancomycin. The Journal of Allergy and Clinical Immunology: In Practice, 12(11), 3025-3033.e6. https://doi.org/10.1016/j.jaip.2024.07.028

Vancouver

Lyu S, Oliver ET, Dispenza MC, Chichester KL, Hoffman J, MacGlashan DW, et al. A Skin Testing Strategy for Non–IgE-Mediated Reactions Associated With Vancomycin. The Journal of Allergy and Clinical Immunology: In Practice. 2024;12(11):3025-3033.e6. doi:10.1016/j.jaip.2024.07.028

BibTeX
@article{Lyu2024,
  author = {Lyu, Siyan and Oliver, Eric T and Dispenza, Melanie C and Chichester, Kristin L and Hoffman, Jennifer and MacGlashan, Donald W and Adkinson, N Franklin and Phillips, Elizabeth J and Alvarez-Arango, Santiago},
  title = {A Skin Testing Strategy for Non–IgE-Mediated Reactions Associated With Vancomycin},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2024},
  volume = {12},
  number = {11},
  pages = {3025--3033.e6},
  doi = {10.1016/j.jaip.2024.07.028}
}
Kostenlos starten →